doxercalciferol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
Vitamin D analogues/derivatives	957	54573-75-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: hectorol doxercalciferol	decrease of bone density caused by prednisolone was prevented by above cpd; decreases number of osteoclast areas in normal rats; RN given refers to (1alpha,3beta,5Z,7E,22E)-isomer Molecular weight: 412.66 Formula: C28H44O2 CLOGP: 8.16 LIPINSKI: 1 HAC: 2 HDO: 2 TPSA: 40.46 ALOGS: -5.39 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

hectorol
doxercalciferol

decrease of bone density caused by prednisolone was prevented by above cpd; decreases number of osteoclast areas in normal rats; RN given refers to (1alpha,3beta,5Z,7E,22E)-isomer

Molecular weight: 412.66
Formula: C28H44O2
CLOGP: 8.16
LIPINSKI: 1
HAC: 2
HDO: 2
TPSA: 40.46
ALOGS: -5.39
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
June 9, 1999	FDA	GENZYME CORP

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	185.77	32.78	103	1306	310584	63177029
Peritonitis bacterial	69.17	32.78	17	1392	4862	63482751
Pruritus	63.66	32.78	57	1352	361396	63126217
Dyspnoea	50.41	32.78	67	1342	661246	62826367
Blood parathyroid hormone abnormal	43.53	32.78	7	1402	225	63487388
Vomiting	41.45	32.78	56	1353	559561	62928052
Unresponsive to stimuli	40.05	32.78	18	1391	33798	63453815

Showing 1 to 7 of 7 entries

Previous1Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	149.92	33.32	68	1214	80461	34875188
Pruritus	60.08	33.32	46	1236	141935	34813714
Unresponsive to stimuli	46.95	33.32	22	1260	27547	34928102
Dyspnoea	39.80	33.32	58	1224	376724	34578925
Flushing	37.78	33.32	20	1262	32400	34923249
Blood parathyroid hormone increased	36.88	33.32	9	1273	1505	34954144
Blood parathyroid hormone abnormal	35.53	33.32	6	1276	156	34955493

Showing 1 to 7 of 7 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	331.25	30.67	169	2379	298747	79443093
Pruritus	104.70	30.67	92	2456	394556	79347284
Peritonitis bacterial	89.96	30.67	26	2522	9541	79732299
Unresponsive to stimuli	83.39	30.67	39	2509	55749	79686091
Dyspnoea	63.34	30.67	104	2444	856921	78884919
Peritoneal dialysis complication	59.28	30.67	14	2534	2340	79739500
Vomiting	52.03	30.67	83	2465	665745	79076095
Blood parathyroid hormone abnormal	50.62	30.67	9	2539	366	79741474
Flushing	48.71	30.67	32	2516	88236	79653604
Blood parathyroid hormone increased	44.44	30.67	12	2536	3433	79738407

Showing 1 to 10 of 13 entries

Previous1 2Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	H05BX03	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS CALCIUM HOMEOSTASIS ANTI-PARATHYROID AGENTS Other anti-parathyroid agents
CHEBI has role	CHEBI:50188	provitamins
CHEBI has role	CHEBI:50646	antiosteoporotic
CHEBI has role	CHEBI:71212	prohormones
FDA CS	M0007651	Ergocalciferols
FDA EPC	N0000175907	Vitamin D2 Analog
MeSH PA	D050071	Bone Density Conservation Agents
MeSH PA	D018977	Micronutrients
MeSH PA	D014815	Vitamins

Showing 1 to 9 of 9 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Hyperparathyroidism Secondary to Chronic Renal Failure with Dialysis	indication
Hyperparathyroidism Secondary to Chronic Renal Failure	off-label use
Hyperphosphatemia	contraindication	20165001	DOID:0050459
Hypervitaminosis D	contraindication	27712000	DOID:9971
Hypoparathyroidism	contraindication	36976004	DOID:11199
Hypercalcemia	contraindication	66931009	DOID:12678
Disease of liver	contraindication	235856003	DOID:409

Showing 1 to 7 of 7 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.7	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Vitamin D3 receptor	Nuclear hormone receptor	P11473	VDR_HUMAN	AGONIST				UNKNOWN	CHEMBL

Showing 1 to 1 of 1 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
007891	NDDF
11516	RXNORM
116094003	SNOMEDCT_US
126234006	SNOMEDCT_US
211288	MMSL
2790	IUPHAR_LIGAND_ID
30992	MMSL
3DIZ9LF5Y9	UNII
4021201	VUID
4021201	VANDF

Showing 1 to 10 of 22 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Doxercalciferol	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0338	CAPSULE	0.50 ug	ORAL	ANDA	24 sections
Doxercalciferol	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0339	CAPSULE	2.50 ug	ORAL	ANDA	24 sections
Doxercalciferol	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0388	CAPSULE	1 ug	ORAL	ANDA	24 sections
DOXERCALCIFEROL	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1330	INJECTION, SOLUTION	2 ug	INTRAVENOUS	NDA	26 sections
DOXERCALCIFEROL	HUMAN PRESCRIPTION DRUG LABEL	1	0409-1331	INJECTION, SOLUTION	2 ug	INTRAVENOUS	NDA	26 sections
Doxercalciferol	HUMAN PRESCRIPTION DRUG LABEL	1	0641-6154	INJECTION	2 ug	INTRAVENOUS	ANDA	23 sections
Doxercalciferol	HUMAN PRESCRIPTION DRUG LABEL	1	0955-1720	CAPSULE	0.50 ug	ORAL	NDA authorized generic	26 sections
Doxercalciferol	HUMAN PRESCRIPTION DRUG LABEL	1	0955-1721	CAPSULE	1 ug	ORAL	NDA authorized generic	26 sections
Doxercalciferol	HUMAN PRESCRIPTION DRUG LABEL	1	0955-1722	CAPSULE	2.50 ug	ORAL	NDA authorized generic	26 sections
Doxercalciferol	HUMAN PRESCRIPTION DRUG LABEL	1	17478-987	INJECTION, SOLUTION	2 ug	INTRAVENOUS	ANDA	25 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next